Merck's RNAi Trash is Alnylam's Treasure

Alnylam acquired Merck's RNAi patent portfolio for a fraction of Merck's cost. Is this a good deal for both parties?

Jan 23, 2014 at 8:00AM

The tussle over Tuschl patents came to an end earlier this month when Alnylam (NASDAQ:ALNY) orchestrated a $175 million acquisition of Merck's (NYSE:MRK) RNAi business.

Alnylam has long made hay from founder Thomas Tushcl's RNAi patents. Those patents, which laid the groundwork for developing RNAi compounds, have been at the heart of a series of deals stretching from Roche's (NASDAQOTH:RHHBY) licensing pact with Alnylam in the late 2000's to Sanofi (NYSE:SNY) tying a bow on a $700 million equity deal with Alynylam this month.  Those patents have also been the source of legal wrangling stretching back to Merck's billion dollar acquisition of Sirna Therapeutics in 2006.  

The long winding path back home
Merck had hoped acquiring Sirna would catapult it into the lead in what was expected to be a rapidly growing market for targeted RNAi treatments.  Why? Because Sirna had licensed the Tuschl 1 patent series from UMass in 2003.  Merck believed those Tuschl 1 patents could short-circuit being shut-out from access to the Tuschl 2 patents controlled by Alnylam if Alnylam linked up with a competitor.

Merck turned out to be only half-right. Roche gave Alnylam $331 million upfront and took an equity stake in Alnylam in 2007 and  Alnylam ended its collaboration deal with Merck a couple months later. 

However, the Tuschl 1 patents didn't pan out to be as strong as previously hoped and uncertainty tied to which patent series covered what technology resulted in a wave of lawsuits.  One of those suits was settled in 2011 by an agreement that included Alnylam issuing a sublicense to Merck for access to Tuschl 2.   

Despite that settlement, the overhang of patent uncertainty, coupled with an inability to quickly develop a safe, marketable drug, meant Merck was faced with a tough decision.

It could double down on RNAi hoping for a breakthrough, or shelve development to focus on compounds closer to commercialization. Facing the loss of $5 billion in annual sales tied to patent expiration for Merck's Singulair in 2012, Merck decided to cut bait on RNAi in 2011 to focus on drugs further along in its pipeline.   

Buying on the cheap
It's likely Alnylam wasn't interested in another player gaining access to its Tuschl 2 patents by acquiring the rights held by Merck's RNAi business.  

It's also likely Alnylam was interested in potentially valuable intellectual property held by Merck given Merck and Roche had been researching the use of polyconjugates as a way to more safely deliver RNAi therapies. Roche sold off its polyconjugate intellectual property to Arrowhead Research (Nasdaq: ARWR) in 2011 after abandoning its RNAi research program in 2010.  

And Alnylam has a license to that technology from Arrowhead for an undisclosed therapy tied to its Alnylam's plans to have five compounds in human trials by 2015.  

As a result, Alnylam's deal with Merck strengthens its patent portfolio, giving its R&D department additional depth for a fraction of the $1 billion plus Merck had sunk into it and for a fraction of the cost it may eventually have paid Arrowhead to expand its relationship with them.

All isn't lost
For Merck, moving out of the RNAi research field was costly.  The company not only spent a billion acquiring Sirna, but likely invested hundreds of millions more in R&D that ended up on the cutting room floor.  

However, inking the deal with Alnylam means the two are working together for the first time since the companies went their separate ways in 2007.  And while the $175 million purchase price is a fraction of Merck's overall investment, Merck may find the value of the deal climbs thanks to an opportunity to earn milestones and royalties.  

Additionally, Merck could also benefit further from Alnylam's success given $150 million of the $175 million purchase price was paid in Alnylam stock.  

Fool-worthy final thoughts
Thanks to Sanofi, Alnylam has plenty of cash on the books to bring along its late stage TTR program, advance its hemophilia and complement-mediated hematology disease programs further into clinic, and make the most of its newly acquired Merck assets.  If those programs work out as hoped, Alnylam may finally fulfill its promise to be the big winner in commercializing RNAi therapies.  

As for Merck, writing down the assets based on Alnylam's sales price should offers some support to its financials short term while Merck may also find itself earning margin friendly milestones and royalties long term.  As a result, investors should consider the deal a win for Alnylam and a potential win for Merck, depending on Alnylam's success.

Rock solid dividend stocks
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it’s true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor’s portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers